Latest News
Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
08 September 2023
NEW YORK, September 8, 2023 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the Company will virtually present and host...
Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance
06 September 2023
- The authors conclude that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)”
- FDA has cleared the IND for...
Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer
23 August 2023
- Leadership Addition Strengthens Company's Commitment to Advancing Innovative Therapies
NEW YORK, August 23, 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies...
Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology
23 August 2023
NEW YORK, August 23 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced an oral presentation of “Nasal anti-CD3 mAb induces...
Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's Disease
17 August 2023
Media: Neurology Live Coverage: FDA Clears IND to Test Intranasal Foralumab in Alzheimer Disease
16 August 2023
FDA Clears IND to Test Intranasal Foralumab in Alzheimer Disease
Aug 15, 2023
Foralumab, a therapy designed to bind to T cell receptor, is about to be assessed in phase 2 trials of patients with non-active secondary progressive multiple...
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease
15 August 2023
- Foralumab to advance into Phase 2 human clinical trials using the world’s only fully human intranasal anti-CD3 monoclonal antibody
- Trial to be overseen by Brigham and Women’s...
Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice
21 July 2023
New York, July 21, 2023 – Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today disclosed the receipt of a notice (the “Notice”) on...
Media: Jane King interviews Matthew Davis, M.D., Chief Medical Officer, Tiziana Life Sciences
23 June 2023
Media: Neurology Live Coverage: Decreased Microglial Activation Observed in Foralumab-Treated Patients With Secondary Progressive MS
15 June 2023
Through an expanded access program, new announced data from a small cohort of patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with foralumab (Tiziana Life Sciences), an investigational anti-CD3 monoclonal antibody, showed reduction in microglial activation after 3 months...